Cargando…

PB2040: INTERRELATION BETWEEN JAK2 V617F MUTATION AND THE INCIDENCE OF THROMBOTIC EVENTS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

Detalles Bibliográficos
Autores principales:	Nikolova, D., Yordanov, A., Damyanova, V., Radinov, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429473/ http://dx.doi.org/10.1097/01.HS9.0000850992.86552.90

Ejemplares similares

PB2193: JAK2 V617F MUTATION BURDEN DETECTION AND RELATIONSHIP WITH LABORATORY CHARACTERISTICS IN MYELOPROLIFERATIVE NEOPLASMS
por: MA, Xuefei, et al.
Publicado: (2023)

Janus Kinase V617F Mutation Detection in Patients with Myelofibrosis
por: Nikolova, D, et al.
Publicado: (2019)

PB2192: JAK2 V617F ALLELE BURDEN AND THROMBOTIC EVENTS IN PATIENTS WITH JAK2 V617F POSITIVE POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA AT HIGH RISK OF THROMBOSIS
por: Hwang, Yun Hui, et al.
Publicado: (2023)

PB2237: NON-THROMBOTIC INCREASED PORTAL VENOUS PRESSURE IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: IS IT JUST A HYPOTHESIS?
por: Yokus, Osman, et al.
Publicado: (2023)

PB2178: EVALUATION OF JAK2 EXON 12 MUTATIONS IN PATIENTS WITH JAK2 (V617F)-NEGATIVE POLYCYTHEMIA VERA
por: Khosravi, Sahar, et al.
Publicado: (2023)

Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms
por: Stein, Brady L., et al.
Publicado: (2011)

Jak2V617F myeloproliferative neoplasm stem cells and interferon-alpha
por: Lane, Steven W., et al.
Publicado: (2013)

Detection of JAK2 V617F mutation increases the diagnosis of myeloproliferative neoplasms
por: ZHANG, SHU-PENG, et al.
Publicado: (2015)

PB2049: MEXICAN REGISTRY OF MYELOPROLIFERATIVE NEOPLASMS. INITIAL REPORT
por: De La Peña Celaya, J. A., et al.
Publicado: (2022)

PB2250: THE IMPACT OF JAK2V617F MUTATION POSITIVITY IN ESSENTIAL THROMBOCYTHEMIA:ABOUT 74 CASES.
por: Cheffai, Arij, et al.
Publicado: (2023)

JAK2V617F mRNA metabolism in myeloproliferative neoplasm cell lines
por: Nauroy, P, et al.
Publicado: (2014)

Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice
por: Shi, Kaiyao, et al.
Publicado: (2014)

The Burden of JAK2V617F Mutated Allele in Turkish Patients With Myeloproliferative Neoplasms
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2015)

Reversine exhibits antineoplastic activity in JAK2(V617F)-positive myeloproliferative neoplasms
por: Lima, Keli, et al.
Publicado: (2019)

Hematopoietic fitness of JAK2(V617F) myeloproliferative neoplasms is linked to clinical outcome
por: Abu-Zeinah, Ghaith, et al.
Publicado: (2022)

PB2041: EVALUATION OF THE PROGNOSTIC VALUE OF THROMBOPHILIA MARKERS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
por: Makarik, T., et al.
Publicado: (2022)

PB2054: HIP AND KNEE OSTEOARTHRITIS IN PHILADELPHIA CHROMOSOME-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Holik, H., et al.
Publicado: (2022)

PB2053: PRIMARY ARTERIAL HYPERTENSION IN MYELOPROLIFERATIVE NEOPLASMS: A SYSTEMATIC REVIEW
por: Gaman, M.-A., et al.
Publicado: (2022)

PB2171: POTENTIAL ROLE OF FACTOR XII POLYMORPHISM IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
por: Efremova, Elizaveta, et al.
Publicado: (2023)

JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms
por: Gäbler, Karoline, et al.
Publicado: (2013)

JAK out of the box: myeloproliferative neoplasms--associated JAK2 V617F mutations contribute to aortic aneurysms
por: Elf, Shannon E.
Publicado: (2021)

Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2015)

Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1β and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms
por: Allain-Maillet, Sophie, et al.
Publicado: (2020)

Metformin exerts multitarget antileukemia activity in JAK2(V617F)-positive myeloproliferative neoplasms
por: Machado-Neto, João Agostinho, et al.
Publicado: (2018)

The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms
por: Zhan, H, et al.
Publicado: (2018)

Expression of CD markers in JAK2(V617F) positive myeloproliferative neoplasms: Prognostic significance
por: Shahrabi, Saeid, et al.
Publicado: (2018)

Erythrocyte-derived microvesicles induce arterial spasms in JAK2(V617F) myeloproliferative neoplasm
por: Poisson, Johanne, et al.
Publicado: (2020)

Platelet function studies in myeloproliferative neoplasms patients with Calreticulin or JAK2(V617F) mutation
por: Guy, Alexandre, et al.
Publicado: (2023)

Contributions of bone marrow monocytes/macrophages in myeloproliferative neoplasms with JAK2(V617F) mutation
por: Fan, Wenjuan, et al.
Publicado: (2023)

Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative Neoplasms
por: Yönal-Hindilerden, İpek, et al.
Publicado: (2023)

Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis
por: Guy, Alexandre, et al.
Publicado: (2020)

PB2212: ABDOMINAL AORTIC CALCIFICATION IN PATIENTS NEWLY DIAGNOSED WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASM
por: Lee, Myung-Won, et al.
Publicado: (2023)

PB2179: ALGORITM OF MOLECULAR GENETIC EXAMINATION OF PATIENTS WITH PH-NEGATIVE CRONIC MYELOPROLIFERATIVE NEOPLASM
por: Voroniak, Myroslav, et al.
Publicado: (2023)

PB2189: UNUSUAL SITE THROMBOSIS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: THE EXPERIENCE WITH 66 CONSECUTIVE CASES.
por: Morsia, Erika, et al.
Publicado: (2023)

The implication of identifying JAK2(V617F) in myeloproliferative neoplasms and myelodysplastic syndromes with bone marrow fibrosis
por: Olsen, Randall J., et al.
Publicado: (2008)

Transient ischemic attacks as the first presentation of JAK2-V617F positive chronic myeloproliferative neoplasm
por: Kalala, Fani, et al.
Publicado: (2012)

Allelic Expression Imbalance of JAK2 V617F Mutation in BCR-ABL Negative Myeloproliferative Neoplasms
por: Kim, Hye-Ran, et al.
Publicado: (2013)

Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis
por: Shimizu, Takafumi, et al.
Publicado: (2016)

CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms
por: Belcic Mikic, Tanja, et al.
Publicado: (2019)

Soluble interleukin-6 receptor in patients with JAK2V617F somatic mutation and myeloproliferative neoplasm
por: Garbers, Christoph, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3lonsgh0rfn4d8n4a99smnl26j